⌛ Did you miss ProPicks’ 13% gains in May? Subscribe now & catch June’s top AI-picked stocks early.Unlock Stocks

European shares slip from 20-month highs; Apple suppliers wobble

Published 04/05/2017, 02:26 am
Updated 04/05/2017, 02:30 am
European shares slip from 20-month highs; Apple suppliers wobble
DE40
-
MBGn
-
STMPA
-
NOVOb
-
TYRES
-
BMWG
-
BOSSn
-
AAPL
-
NTRS
-
DLGS
-
CEY
-
STOXX
-
AMS
-
SXPP
-

* Apple suppliers fall on weak iPhone sales

* Novo Nordisk jumps on profit beat

* Profit outlook rosier for Fresenius

* Miners at four-month low (Adds quote and detail, updates prices at close)

By Helen Reid and Kit Rees

LONDON, May 3 (Reuters) - European shares slipped slightly from the 20-month highs they hit in the previous session, as investors locked in profits following some underwhelming company results on Wednesday.

Europe's STOXX 600 .STOXX index was flat in percentage terms at its close, having spent most of the session in negative territory.

Shares in several Apple AAPL.O suppliers fell after the smartphone giant reported a surprise dip in sales of its flagship iPhone. Semiconductor DLGS.DE shares slid 2.5 percent. They had plummeted 14 percent in April on fears over Apple bringing some of its components in-house.

"Dialog has been trying to diversify for a number of years to different sources, but unfortunately if your key relationship is with Apple and that's because you have got great products, there's risk and opportunity very closely aligned in that," said Neil Campling, technology analyst at Northern Trust (NASDAQ:NTRS).

Peers AMS AMS.S and STMicro STM.MI also fell 1.2 and 1.8 percent respectively.

Shares in German luxury retailer Hugo Boss BOSSn.DE dropped nearly 3 percent after online sales fell 27 percent due to fewer visitors to its website. bluechip automakers Daimler DAIGn.DE and BMW BMWG.DE were also on the back foot after disappointing April auto sales in the U.S.

Gains among healthcare stocks supported Germany's DAX .GDAXI index, which rose 0.2 percent and touched a fresh all-time high.

Fresenius hit a record high, up 2.6 percent, after it raised its 2017 profit forecast after demand for its generic infusion drugs boosted first-quarter income 28 percent. do not believe investors were anticipating another guidance raise and will be relieved by the Kabi strength," said UBS analysts, referring to the company's infusion segment.

Danish drugmaker Novo Nordisk NOVOb.CO jumped to the top of the STOXX 600, up 6.8 percent after it beat estimates for first-quarter profit and nudged up its full-year outlook. underwhelming results weighed on Finland's Nokian Tyres NRE1V.HE , down 5.7 percent after it missed estimates for operating profit. CEY.L sank nearly 6 percent after posting a 28-percent fall in first-quarter pretax profit. It dragged Europe's miners .SXPP down 2.5 percent to a four-month low. first-quarter earnings are expected to increase 10.5 percent from the first quarter of 2016, or 6.2 percent excluding the energy sector, Thomson Reuters data showed.

Of 111 companies to have reported earnings so far, 70.3 percent exceeded analyst estimates, above the 49.5 percent of beats in a typical quarter.

"For the first time in many years we're seeing good momentum and strong earnings growth in European equities," said Chris Dyer, director of global equity at Eaton Vance.

"I think investors are putting money into European equities, we're starting to see that in flow data since the beginning of this year after substantial outflows last year due to political and economic uncertainty coming into 2017."

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.